HCA Healthcare (HCA)
NYSE: HCA · Medical Facilities · Nashville, TN
Our rating: Positive
Positive reaffirmed at $473.19, moderate conviction, October 30, 2026.
Breaks if: The Positive call rests on continued cash generation and revenue momentum. It would be wrong if free-cash-flow margin — free cash flow divided by revenue — falls below 8% for two consecutive quarterly reports (the current figure is approximately 10.2%) or if year-over-year revenue growth decelerates to below 3% in two straight prints, either of which would indicate the operating durability assumed here has broken down. A 20% drawdown from the current price within twelve months, absent a broad market move of comparable size, would also signal that the market is pricing in a deterioration this desk has not yet seen in the filings.
Key figures
| Market value | $99.3B |
|---|---|
| Revenue, last 12 months | $78.7B |
| Net income, last 12 months | $6.8B |
| Free cash flow, last 12 months | $6.0B |
| Price to earnings | 14.7× |
| Free cash flow yield | 6.0% |
| Dividend yield | 0.6% |
| Operating margin | n/a |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.26 |
| Volatility, annualized | 29.6% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $19.8B | 3.6% | $7.27 | $3.1B |
| June 30, 2026 | $20.2B | 8.7% | $7.62 | $1.1B |
| March 31, 2026 | $19.1B | 4.3% | $7.15 | $895M |
| December 31, 2025 | $19.5B | 6.7% | $8.10 | $870M |
| September 30, 2025 | $19.2B | 9.6% | $6.96 | $3.1B |
| June 30, 2025 | $18.6B | 6.4% | $6.83 | $3.0B |
| March 31, 2025 | $18.3B | 5.7% | $6.45 | $660M |
| December 31, 2024 | $18.3B | 5.7% | $5.63 | $1.3B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $20.7B: Claude 42%, Gemini 40%, Mistral 40%
- Diluted earnings per share are at least $8.10: Claude 48%, Gemini 70%, Mistral 30%
- Free cash flow for the quarter is at least $0.87B: Claude 62%, Gemini 90%, Mistral 85%
18 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.